Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6435998rdf:typepubmed:Citationlld:pubmed
pubmed-article:6435998lifeskim:mentionsumls-concept:C0036019lld:lifeskim
pubmed-article:6435998lifeskim:mentionsumls-concept:C0005064lld:lifeskim
pubmed-article:6435998lifeskim:mentionsumls-concept:C0242485lld:lifeskim
pubmed-article:6435998lifeskim:mentionsumls-concept:C0851347lld:lifeskim
pubmed-article:6435998lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:6435998lifeskim:mentionsumls-concept:C0079809lld:lifeskim
pubmed-article:6435998lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:6435998pubmed:issue3lld:pubmed
pubmed-article:6435998pubmed:dateCreated1984-12-11lld:pubmed
pubmed-article:6435998pubmed:abstractTextEffects of a single dose of 0.25 mg triazolam p.o. on saccadic eye movements were studied in 6 healthy volunteers. Triazolam was chosen because of its short half-life of 2.5 hours. Peak velocity, duration, acceleration/deceleration index, ratio of hypometric saccades and number of corrective saccades were measured before and at repeated intervals after triazolam administration over a period of 9 hours. Maximal change compared with baseline was observed 90 min. after drug administration. After 9 hours baseline values were reached. As with other benzodiazepines, peak velocity and duration of saccades were the most reliable parameters. Additionally, the number of corrective saccades was found to be a sensitive indicator of drug-induced impairment of oculomotor performance. The present study again emphasises the importance of saccadic eye movements for assessing effects of sedative drugs.lld:pubmed
pubmed-article:6435998pubmed:languagegerlld:pubmed
pubmed-article:6435998pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6435998pubmed:citationSubsetIMlld:pubmed
pubmed-article:6435998pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6435998pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6435998pubmed:statusMEDLINElld:pubmed
pubmed-article:6435998pubmed:monthSeplld:pubmed
pubmed-article:6435998pubmed:issn0012-7590lld:pubmed
pubmed-article:6435998pubmed:authorpubmed-author:MeienbergOOlld:pubmed
pubmed-article:6435998pubmed:authorpubmed-author:FischH UHUlld:pubmed
pubmed-article:6435998pubmed:authorpubmed-author:Schlaginhaufe...lld:pubmed
pubmed-article:6435998pubmed:issnTypePrintlld:pubmed
pubmed-article:6435998pubmed:volume15lld:pubmed
pubmed-article:6435998pubmed:ownerNLMlld:pubmed
pubmed-article:6435998pubmed:authorsCompleteYlld:pubmed
pubmed-article:6435998pubmed:pagination145-50lld:pubmed
pubmed-article:6435998pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:meshHeadingpubmed-meshheading:6435998-...lld:pubmed
pubmed-article:6435998pubmed:year1984lld:pubmed
pubmed-article:6435998pubmed:articleTitle[Saccadic eye movements as a measure of the pharmacodynamics of benzodiazepines. Evaluation of various occulographic parameters].lld:pubmed
pubmed-article:6435998pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6435998pubmed:publicationTypeEnglish Abstractlld:pubmed